Is β-interferon a promising therapeutic option for the management of hepatitis C?

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 6, 2009, Pages 1097-1103

  Hosseini Moghaddam, Seyed Mohammadmehdi ^a   Mousavi, Afkham ^a   Alavian, Seyed Moayed ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cytokines; Haemodialysis; HCV

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; PEGINTERFERON ALPHA; RECOMBINANT BETA INTERFERON; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ANXIETY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; AUTOIMMUNE HEMOLYTIC ANEMIA; DEPRESSION; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; HEMODIALYSIS; HEPATITIS C; HUMAN; HYPOALBUMINEMIA; INJECTION SITE SCAR; INJECTION SITE ULCER; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; IRRITABILITY; KIDNEY ALLOGRAFT REJECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER INJURY; MONARTHRITIS; MONOCLONAL IMMUNOGLOBULINEMIA; MONOTHERAPY; MYALGIA; NEPHROTOXICITY; POLIOMYELITIS; PROTEINURIA; PSYCHOSOMATIC DISORDER; REVIEW; SIDE EFFECT; SKIN ULCER; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; WEAKNESS; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; CARRIER STATE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-BETA; TREATMENT OUTCOME;

EID: 65749103817     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp092     Document Type: Review

References (59)

1. Baron S, Albrecht T. Medical Microbiology. Galveston, TX: University of Texas Medical Branch at Galveston, Dept. of Microbiology and Immunology, 1996.
2. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 8-32.
3. Montalto G, Tripi S, Cartabellotta A et al. Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon. Am J Gastroenterol 1998; 93: 950-3.
4. Barbaro G, Di Lorenzo G, Soldini M et al. Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators. Scand J Gastroenterol 1999; 34: 928-33.
5. Kim KI, Sasase N, Taniguchi M et al. Interferon-beta induction/ interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Int J Clin Pharmacol Res 2005; 25: 71-6.
6. Tan FU, Cetinkaya H, Erden E et al. Dual benefit from intramuscular interferon-beta treatment in a patient with multiple sclerosis and chronic hepatitis-C virus infection. Hepatogastroenterology 2002; 49: 1686-7.
7. Nomura H, Sou S, Nagahama T et al. Efficacy of early retreatment with interferon beta for relapse in patients with genotype Ib chronic hepatitis C. Hepatol Res 2004; 28: 36-40.
8. Komorizono Y, Sako K. Natural beta interferon as an initial treatment for the elderly with chronic hepatitis C. Am J Gastroenterol 2003; 98: 2103-5.
9. Castro A, Suarez D, Inglada L et al. Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C. J Interferon Cytokine Res 1997; 17: 27-30.
10. Terranova R, Luca S. Preliminary results of beta-interferon treatment in the elderly. Control Clin Trials 1996; 17: 123-9.
11. Minohara Y, Kato T, Kanki K et al. Relation between serum hepatitis C virus-RNA levels and efficacy of interferon-beta therapy. Acta Paediatr Jpn 1995; 37: 530-3.
12. Ikeda K, Arase Y, Saitoh S et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32: 228-32.
13. Murata M, Nabeshima S, Kikuchi K et al. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine 2006; 33: 121-8.
14. Kakumu S, Yoshioka K, Wakita T et al. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993; 105: 507-12.
15. Pellicano R, Craxi A, Almasio PL et al. Interferon beta-1a alone or in combination with ribavirin: A randomized trial to compare efficacy and safety in chronic hepatitis C. World J Gastroenterol 2005; 11: 4484-9.
16. Han Q, Liu Z, Kang W et al. Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: A randomized, placebo-controlled trial. Dig Dis Sci 2008; 53: 2238-45.
17. Bernardinello E, Cavalletto L, Chemello L et al. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology 1999; 46: 3216-22.
18. Fukutomi T, Fukutomi M, Iwao M et al. Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C. Med Sci Monit 2000; 6: 692-8.
19. Kobayashi Y, Watanabe S, Konishi M et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Hepatology 1993; 18: 1319-25.
20. Kurosaki M, Enomoto N, Murakami T et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 1997; 25: 750-3.
21. Cheng PN, Marcellin P, Bacon B et al. Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: A better response in Chinese patients. J Viral Hepat 2004; 11: 418-26.
22. Shiratori Y, Nakata R, Shimizu N et al. High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group. Dig Dis Sci 2000; 45: 2414-21.
23. Mochizuki K, Kagawa T, Takashimizu S et al. Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C. World J Gastroenterol 2004; 10: 733-6.
24. Fukutomi T, Nakamuta M, Fukutomi M et al. Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapy. J Hepatol 2001; 34: 100-7.
25. Enomoto M, Nishiguchi S, Tanaka M et al. Dynamics of hepatitis C virus monitored by real-time quantitative polymerase chain reaction during first 2 weeks of IFN-beta treatment are predictive of long-term therapeutic response. J Interferon Cytokine Res 2002; 22: 389-95.
26. Nakajima F, Fukii M, Kitamura T et al. A case report of interferon beta monotherapy for high hepatitis C viral load in dialysis patients. Ther Apher Dial 2007; 11: 306-8.
27. Uchihara M, Izumi N, Sakai Y et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: Increased serum levels of interferon. Nephron 1998; 80: 51-6.
28. Rostaing L, Chatelut E, Payen JL et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implications. J Am Soc Nephrol 1998; 9: 2344-8.
29. Nakayama H, Shiotani S, Akiyama S et al. Pharmacokinetic study of human natural beta-interferon in patients with end-stage renal failure. Clin Nephrol 2001; 56: 382-6.
30. Hanafusa T, Ichikawa Y, Kishikawa H et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66: 471-6.
31. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group. J Hepatol 1990; 11 Suppl 1: S31-5.
32. Konishi I, Horiike N, Michitaka K et al. Renal transplant recipient with chronic hepatitis C who obtained sustained viral response after interferon-beta therapy. Intern Med 2004; 43: 931-4.
33. Kakizaki S, Takagi H, Yamada T et al. Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C. J Viral Hepat 1999; 6: 315-9.
34. Ikeda F, Shimomura H, Miyake M et al. Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-beta. J Interferon Cytokine Res 2000; 20: 831-6.
35. Kaito M, Yasui-Kawamura N, Iwasa M et al. Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C. Hepatogastroenterology 2003; 50: 775-8.
36. Nakajima H, Shimomura H, Iwasaki Y et al. Anti-viral actions and viral dynamics in the early phase of three different regimens of interferon treatment for chronic hepatitis C: Differences between the twice-daily administration of interferon-beta treatment and the combination therapy with interferon-alpha plus ribavirin. Acta Med Okayama 2003; 57: 217-25.
37. Yoshioka K, Yano M, Hirofuji H et al. Randomized controlled trial of twice-a-day administration of natural interferon beta for chronic hepatitis C. Hepatol Res 2000; 18: 310-9.
38. Saito H, Tada S, Ebinuma H et al. Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C. Keio J Med 2006; 55: 111-7.
39. Shiratori Y, Perelson AS, Weinberger L et al. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta. J Hepatol 2000; 33: 313-22.
40. Castro A, Carballo E, Dominguez A et al. Tolerance and efficacy of subcutaneous interferon-beta administered for treatment of chronic hepatitis C. J Interferon Cytokine Res 1997; 17: 65-7.
41. Habersetzer F, Boyer N, Marcellin P et al. A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C. Liver 2000; 20: 437-41.
42. Calleri G, Colombatto P, Gozzelino M et al. Natural beta interferon in acute type-C hepatitis patients: A randomized controlled trial. Ital J Gastroenterol Hepatol 1998; 30: 181-4.
43. Fesce E, Airoldi A, Mondazzi L et al. Intramuscular beta interferon for chronic hepatitis C: Is it worth trying? Ital J Gastroenterol Hepatol 1998; 30: 185-8.
44. Furusyo N, Hayashi J, Ohmiya M et al. Differences between interferon-alpha and beta treatment for patients with chronic hepatitis C virus infection. Dig Dis Sci 1999; 44: 608-17.
45. Perez R, Pravia R, Artimez ML et al. Clinical efficacy of intramuscular human interferon-beta vs. interferon-alpha 2b for the treatment of chronic hepatitis C. J Viral Hepat 1995; 2: 103-6.
46. Miyajima I, Sata M, Uchimura Y et al. Sequential interferon-alpha and beta treatment in patients with chronic hepatitis C. Kansenshogaku Zasshi 1996; 70: 690-5.
47. Ohnishi K, Nomura F, Iida S. Treatment of posttransfusion non-A, non-B acute and chronic hepatitis with human fibroblast beta-interferon: A preliminary report. Am J Gastroenterol 1989; 84: 596-600.
48. Festi D, Sandri L, Mazzella G et al. Safety of interferon beta treatment for chronic HCV hepatitis. World J Gastroenterol 2004; 10: 12-6.
49. Okuno H, Takasu M, Kano H et al. Depression of drug-metabolizing activity in the human liver by interferon-beta. Hepatology 1993; 17: 65-9.
50. Villa E, Trande P, Grottola A et al. Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study. Dig Dis Sci 1996; 41: 1241-7.
51. Fujimori K, Mochida S, Matsui A et al. Possible mechanisms of elevation of serum transaminase levels during interferon-beta therapy in chronic hepatitis C patients. J Gastroenterol 2002; 37: 40-6.
52. Malaguarnera M, Restuccia S, Di Fazio I et al. Rapid evolution of chronic viral hepatitis into hepatocellular carcinoma after beta-interferon treatment. Panminerva Med 1999; 41: 59-61.
53. Kado S, Miyamoto J, Komatsu N et al. Type 1 diabetes mellitus caused by treatment with interferon-beta. Intern Med 2000; 39 146-9.
54. Nakamura Y, Hino K. A case of ovulatory cycle-dependent symptoms in woman with previous interferon beta therapy. Endocr J 2005; 52 377-81.
55. Ohno Y, Fujimoto M, Nishimura A et al. Change of peripheral levels of pituitary hormones and cytokines after injection of interferon (IFN)-beta in patients with chronic hepatitis C. J Clin Endocrinol Metab 1998; 83: 3681-7.
56. Gattoni A, Cecere A, Romano C et al. Case report of a monoclonal gammopathy in a patient with chronic hepatitis: Effects of beta-IFN treatment. Panminerva Med 1996; 38: 175-8.
57. Toccaceli F, Rosati S, Scuderi M et al. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. Hepatogastroenterology 1998; 45: 1748-52.
58. Kazuta Y, Watanabe N, Sagawa K et al. A case of autoimmune hemolytic anemia induced by IFN-beta therapy for type-C chronic hepatitis. Fukushima J Med Sci 1995; 41: 43-9.
59. Murata K, Shiraki K, Takase K et al. Mono-arthritis following intensified interferon beta therapy for chronic hepatitis C. Hepatogastroenterology 2002; 49: 1418-9.